Do All People Lose Weight on Ozempic? Genetic & Biomarker Factors

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, not all people lose weight on Ozempic, despite its widespread clinical use. Clinical trials show average weight loss of 4–15% depending on dose and individual factors, but approximately 20–30% of users experience minimal or non-meaningful weight reduction.

Understanding why response varies is essential for treatment planning. Genetic predispositions in peptide signaling pathways, baseline metabolic biomarkers, and lifestyle adherence all influence whether a GLP-1 medication will produce clinically significant results for a specific patient.

The Clinical Reality of Variable GLP-1 Response

Clinical data from Ozempic and Wegovy trials demonstrate heterogeneous weight loss outcomes. Mean reductions range from 4% at lower doses to 15% at maximum doses, but individual results cluster around a wide distribution—some users achieve 20%+ loss while others see minimal change.

This variation is not random. Responders and non-responders differ in baseline insulin sensitivity, appetite-regulation neurobiology, gastrointestinal tolerance, and adherence patterns. Identifying these differences early can guide medication selection and dosing strategy.

Genetic Predispositions That Influence Peptide Signaling Response

Four key genetic variants in peptide regulatory pathways have been associated with differential GLP-1 and metabolic response. These are not deterministic—they represent predispositions that interact with environment, diet, and comorbidities. PlexusDx Precision Peptide Genetic Test evaluates these markers to help provide clinical context.

Genetic Variant	Gene	Associated Pathway	Clinical Relevance
rs6923761	GLP1R	GLP-1 receptor sensitivity	May influence appetite suppression magnitude and gastrointestinal tolerance
rs1800437	GIPR	Glucose-dependent insulinotropic peptide signaling	May affect insulin secretion response and metabolic efficiency
rs9939609	FTO	Energy homeostasis and appetite control	May predispose to greater appetite dysregulation and variable baseline satiety
rs17782313	MC4R	Melanocortin-4 pathway (central appetite)	May influence hypothalamic appetite signaling and weight set-point regulation

Biomarkers Associated with Better GLP-1 Treatment Response

Pre-treatment metabolic biomarkers can help predict likelihood of meaningful response. Patients with baseline hyperinsulinemia, elevated triglycerides, or elevated HbA1c (in type 2 diabetes) often show stronger weight and metabolic improvements because GLP-1 mechanisms directly address these dysregulations.

Conversely, patients with normal fasting insulin, low triglycerides, and no insulin resistance may have smaller absolute weight losses because the medication's mechanism targets pathways already functioning adequately. This doesn't mean these patients shouldn't use GLP-1 therapy—it means providers should set realistic expectations and explore alternative or complementary approaches.

Why Some People Don't Lose Weight on GLP-1 Medications

Medication non-response can occur for several reasons: insufficient receptor sensitivity due to genetic variation, dose too low to reach therapeutic threshold, poor gastrointestinal tolerance limiting dose escalation, concurrent medications affecting metabolism, or inadequate behavioral adherence. Many cases reflect genuine physiological resistance rather than patient failure.

Providers should assess gastrointestinal tolerability, confirm adequate dosing, review for drug-drug interactions, and evaluate lifestyle factors (sleep, stress, physical activity) before concluding that GLP-1 therapy is ineffective. Switching to a different compound, adjusting formulation (oral vs. injection), or adding complementary agents may yield better outcomes.

Who Is Most Likely to Benefit: A Provider Decision Framework

Evidence suggests stronger weight loss in patients with baseline obesity class II–III (BMI >35), type 2 diabetes or prediabetes, insulin resistance markers, elevated inflammatory markers, and metabolic syndrome features. Age <65 and fewer comorbidities also correlate with better tolerance and adherence.

Patients with baseline normal weight, no metabolic dysfunction, or primary goal of modest cosmetic weight loss may benefit less dramatically and should understand realistic expectations. Genetic predisposition testing and biomarker assessment should inform individualized discussions about whether GLP-1 therapy is the optimal choice for that specific person.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test evaluates predispositions in four key variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) within peptide signaling and appetite-regulation pathways. These results may help provide clinical context for why an individual's GLP-1 response might differ from population averages.

The genetic test reveals predispositions in how your body's peptide signaling systems are wired—not exact medication response. A variant in GLP1R, for example, may suggest lower baseline GLP-1 receptor sensitivity, which could inform dose titration strategy or indicate that a different medication class might be considered. Results should always be interpreted with your qualified healthcare provider.

Understanding your genetic predispositions in peptide pathways, combined with baseline biomarker assessment and clinical history, enables a more personalized conversation with your provider about which GLP-1 compound, formulation (oral vs. injection), and dosing schedule aligns with your physiology and goals. This precision-wellness approach moves beyond one-size-fits-all assumptions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.